Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies ITCI in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 2 | 1 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $88.86, a high estimate of $103.00, and a low estimate of $77.00. Marking an increase of 10.55%, the current average surpasses the previous average price target of $80.38.
Interpreting Analyst Ratings: A Closer Look
The standing of Intra-Cellular Therapies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Graig Suvannavejh | Mizuho | Raises | Buy | $96.00 | $82.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Neutral | $77.00 | $67.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $91.00 | $82.00 |
| Joel Beatty | Baird | Raises | Outperform | $103.00 | $83.00 |
| Joseph Thome | TD Cowen | Raises | Buy | $90.00 | $80.00 |
| Ami Fadia | Needham | Maintains | Buy | $82.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $82.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $86.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $101.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $86.00 | - |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $100.00 | $101.00 |
| Ami Fadia | Needham | Raises | Buy | $82.00 | $72.00 |
| Graig Suvannavejh | Mizuho | Raises | Buy | $82.00 | $76.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $86.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Intra-Cellular Therapies. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Intra-Cellular Therapies's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intra-Cellular Therapies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Intra-Cellular Therapies analyst ratings.
About Intra-Cellular Therapies
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Intra-Cellular Therapies's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of 50.41% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -21.73%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -4.79%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Intra-Cellular Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
